Experimental HIV Drugs
Experimental HIV Drugs
ICAAC 2013: New Tenofovir Formulation Has Less Effect on Kidneys and Bones
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 13 September 2013 00:00
- Written by Liz Highleyman
Tenofovir alafenamide (TAF), a new formulation that reaches higher levels in cells but allows for lower dosing, was as effective as the current tenofovir disoproxil fumarate (TDF) formulation but had less impact on markers of kidney function and bone turnover, researchers reported at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this week in Denver.
HIV Treatment Highlights from IAS 2013 [VIDEO]
- Details
- Category: HIV Treatment
- Published on Sunday, 07 July 2013 00:00
- Written by Gregory Fowler
Cal Cohen offers a summary of some of the major studies of antiretroviral treatment strategies presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) last week in Kuala Lumpur.
IAS 2103: Dolutegravir Beats Raltegravir for Treatment-experienced HIV Patients [VIDEO]
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 03 July 2013 00:00
- Written by Gregory Fowler
The once-daily HIV integrase inhibitor dolutegravir demonstrated better efficacy than twice-daily raltegravir (Isentress), with fewer study withdrawal due to virological failure and less drug resistance, according to data from the SAILING trial presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
IAS 2013: Long-acting GSK1265744 and TMC278-LA Appear Safe and Practical in Early Study
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 05 July 2013 00:00
- Written by Liz Highleyman
A combination of antiretroviral drugs in long-acting nanosuspension formulations achieved adequate blood levels and appeared safe in HIV negative study volunteers, offering the potential for a maintenance or PrEP option that could be taken once monthly, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
IAS 2013: Reduced Efavirenz Dose Suppresses HIV as Well as Standard Dose
- Details
- Category: HIV Treatment
- Published on Wednesday, 03 July 2013 00:00
- Written by Liz Highleyman
Lowering the dosage of efavirenz (Sustiva) from 600 to 400 mg in an antiretroviral regimen did not compromise efficacy, and has the potential to substantially reduce treatment cost, according to data from the ENCORE1 study presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
More Articles...
- IAS 2013: Dolutegravir Superior to Raltegravir for Treatment-experienced People with HIV
- New NRTI BMS-986001 Potently Suppresses HIV in Early Monotherapy Study
- Cobicistat Booster Is a Safe and Effective Alternative to Ritonavir
- FDA Declines Approval of Elvitegravir and Cobicistat as Stand-alone HIV Meds
Web Design and Development by